Bidikian, Aram http://orcid.org/0000-0001-5856-5926
Kantarjian, Hagop http://orcid.org/0000-0002-1908-3307
Jabbour, Elias http://orcid.org/0000-0003-4465-6119
Short, Nicholas J. http://orcid.org/0000-0002-2983-2738
Patel, Keyur http://orcid.org/0000-0001-5081-2427
Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Issa, Ghayas C. http://orcid.org/0000-0002-4339-8683
Article History
Received: 22 August 2022
Revised: 6 October 2022
Accepted: 7 October 2022
First Online: 28 October 2022
Competing interests
: HK received research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, Astra Zeneca, Ipsen, Pharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer, Precision Biosciences, Taiho Pharmaceutical Canada. EJ received research grants from Abbvie, adaptive biotechnologies, Amgen, Pfizer, and Takeda; and consultancy fees from Abbvie, adaptive biotechnologies, Amgen, BMS, Genentech, Incyte, Novartis, Pfizer, and Takeda. NJS reports consultancy for Takeda Oncology, Jazz Pharmaceuticals, NGMBio, AstraZeneca, and Amgen; research funding from Takeda Oncology and Astellas; honoraria from Amgen, and Novartis. FR reports honoraria from Astex, Taiho, Bristol Myers Squibb, Xencor, Agios, AstraZeneca, Novartis, AbbVie, Celgene, Jazz, Syros Pharmaceuticals, and Amgen; research funding from Astex, Taiho, Bristol Myers Squibb, Xencor, Agios, Prelude, AbbVie, Celgene, Jazz, Syros Pharmaceuticals, and Amgen; membership on the Board of Directors or advisory committees of Bristol Myers Squibb and Celgene; consultancy for Syros Pharmaceuticals KS received research funding and consultancy fees from Novartis; and is on the advisory board for Daiichi-Sankyo and Pfizer. GCI received research funding from Celgene, Kura Oncology, Syndax and Novartis; and consultancy fees from Novartis and Kura Oncology.